Akero Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
9/10
|
8.18 | 48.77 | -83.23% | -8.2 | -199.81% |
| P/S |
|
0 | 33.76 | -100% |
|
|
| P/BV |
|
2.33 | 4.82 | -51.68% |
|
|
| P/FCF |
|
-17.75 | 61 | -129.1% |
|
|
| Ev/Ebitda |
|
-6.01 | -22.15 | -72.87% |
|
|
| Ev/S |
|
0 | 22.56 | -100% |
|
|
| Ev/FCF |
|
-7.15 | 68.78 | -110.39% |
|
|
| E/P |
|
-0.0588 | 0.0178 | -430.83% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.98 | -100% | 0 | 0% |
| ROE |
|
-28.35 | 9.61 | -394.96% |
|
|
| ROA |
|
-26.15 | 0.3443 | -7696.92% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-32.29 | 15.35 | -310.38% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.1459 | -3.68 | -96.03% | -0.1165 | +25.28% |
| Nеt Debt/Ebitda |
|
1.2 | -3.44 | -135.04% |
|
|
| Debt/Ratio |
|
0.0435 | 0.1985 | -78.1% |
|
|
| Debt/Equity |
|
536.68 | 1.66 | 32186.65% |
|
|
| Debt/Net Income |
|
-0.1662 | 10.32 | -101.61% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5442 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2237 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9889 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4952 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5442 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -56.89 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
225.58 | -54.68 | -512.55% | ||
| Growth impulse Net Income in 5 years |
|
246.84 | -58.33 | -523.18% | ||
| Growth impulse FCF in 5 years |
|
308.02 | -49.48 | -722.51% | ||
| Growth impulse EPS in 5 years |
|
-0.5652 | -32.41 | -98.26% |
IP Score
3.72/10
